You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBC: ENABLE LIFE SCIENCES LLC Topic: PTThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project focuses on the unique combination of cancer-specific antibodies and adoptive Natural Killer (NK) immune cells needed to offer personalizable cancer therapies.This innovation represents a platform technology that can spawn multiple innovative cancer treatments, which could positively impact lif ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase I: Software-Defined Networking and Resource Virtualization in Low Earth Orbit (LEO) Satellite Constellations
SBC: UNINET LLC Topic: SPThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the extension of state-of-the-art terrestrial 5G technologies to non-terrestrial satellite networks. Non-terrestrial networks (NTNs) are the ideal hosts for many commercial applications involving monitoring, reconnaissance, and remote sensing such as agricultural planting, remote factory op ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase II:Smart Shunt to Treat Hydrocephalus
SBC: Madison Scientific, Inc. Topic: MDThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the development of an advanced electromechanical cerebrospinal fluid (CSF) shunt system for the treatment and monitoring of hydrocephalus. Hydrocephalus is caused by an accumulation of CSF occurs within the brain, often causing an increased pressure inside the skull. Most shunts used to re ...
SBIR Phase II 2023 National Science Foundation -
Integrated, Resilient, and Highly Adaptable Aerospace Information Networks
SBC: OWL Integrations, Inc. Topic: X22DOTCSO1United States Air Force S&T identifies five strategic capabilities: 1) Global Persistent Awareness, 2) Resilient Information Sharing, 3) Rapid, Effective Decision-Making, 4) Complexity, Unpredictability, and Mass, and 5) Speed and Reach of Disruption and
STTR Phase II 2023 Department of DefenseAir Force -
STTR Phase I:Next-Gen Radiofrequency Transistors on Silicon via Aligned, Residue-Free Carbon Nanotubes
SBC: SIXLINE SEMICONDUCTOR, INC. Topic: SThe broader/commercial impact of this Small Business Technology Transfer (STTR) Phase I project seeks to overcome the highest risks facing the commercialization of a novel semiconductor for wireless communications devices. As the demand for wireless communication increases (e.g., cell phones, WiFi, Internet of Things devices), wireless component suppliers and manufacturers must utilize new materia ...
STTR Phase I 2023 National Science Foundation -
Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease
SBC: Recombinant Technologies LLC Topic: NIAAbstract Alzheimer’s disease is the most common cause of dementia and fourth most common cause of death. Amyloid-beta (Aβ) plays a crucial role in initiation and progression of Alzheimer’s disease (AD). Removal of circulating Aβ would shift the equilibrium in Aβ levels between brain and blood towards blood. This shift would deplete brain amyloid levels and improve memory. Three commercial m ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.
SBC: ABBRATECH INC. Topic: 400ABSTRACT Antibodies (Abs) are commonly employed in biomedical research to identify and quantify target proteins. However, the specificity, sensitivity and reliability of these Abs can be variable, which is a significant concern in the scientific community. The use of an incorrect Ab can result in misleading or inaccurate results, impeding progress in various areas of biomedical research. In Phase ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Framework for mHealth App Security and Privacy Analysis
SBC: UBITRIX INTERNATIONAL, INC. Topic: NLMPROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Comprehensive Assessment of Cancer Theranostics Response
SBC: AIQ GLOBAL INC Topic: NCIProject SummaryTheranostics combines molecular targeted diagnostic and therapeutic radionuclides for imaging and ther- apy in advanced malignancies, with a projected US market of more than $6.7B. Currently, metastatic castra- tion-resistant prostate cancer (mCRPC) with FDA approved lutetium-177 (177Lu)-based peptide receptor targeting radionuclide therapy (PRRT), represents the largest market. Pro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a sample preparation protocol for 3D kidney ultrastructural analysis and immunolabeling by light microscopy
SBC: panluminate Inc. Topic: 400Abstract The success of cohort studies such as the NIDDK Kidney Precision Medicine Project (KPMP) with its massive amount of samples depends on the cost and time-efficient evaluation of kidney biopsies at multiple scales. Assessing the structure of kidney tissue at the nanoscale (~10 nm) and evaluating the 3-D distribution of protein biomarkers in that context is, however, currently severely limit ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health